CVS Health Corporation (CVS)Â
Largest Insider Buys in Sector
CVS Stock Price History Chart
CVS Stock Performance
About CVS Health Corporation
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Insider Activity of CVS Health Corporation
Over the last 12 months, insiders at CVS Health Corporation have bought $554,173 and sold $2.27M worth of CVS Health Corporation stock.
On average, over the past 5 years, insiders at CVS Health Corporation have bought $663,639 and sold $43.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mahoney Michael F (director) — $1M. LUDWIG EDWARD J (director) — $215,516.
The last purchase of 9,181 shares for transaction amount of $500,294 was made by Mahoney Michael F (director) on 2024‑05‑02.
List of Insider Buy and Sell Transactions, CVS Health Corporation
| 2024-05-02 | director | 1,000 <0.0001% | $53.88 | $53,879 | +4.70% | |||
| 2024-05-02 | director | 9,181 0.0007% | $54.49 | $500,294 | +4.70% | |||
| 2024-02-16 | Sale | EVP and Pres-Pharm, Consumer W | 29,473 0.0023% | $76.95 | $2.27M | -23.09% | ||
| 2023-11-03 | director | 2,000 0.0002% | $70.47 | $140,930 | -3.01% | |||
| 2023-08-03 | Sale | SVP, Cont & Chief Acct Officer | 25,759.26 0.002% | $74.92 | $1.93M | -5.49% | ||
| 2023-05-03 | President and CEO | 14,000 0.0011% | $69.75 | $976,567 | +2.03% | |||
| 2022-12-15 | Sale | EVP & General Counsel | 36,490 0.0028% | $98.24 | $3.58M | -24.78% | ||
| 2022-08-03 | Sale | EVP&President-PharmacyServices | 70,398 0.0052% | $98.00 | $6.9M | -12.65% | ||
| 2022-08-03 | Sale | EVP/Pres, Health Care Benefits | 9,546 0.0007% | $100.00 | $954,600 | -12.65% | ||
| 2022-06-28 | Sale | EVP & General Counsel | 50,502 0.0039% | $95.00 | $4.8M | -1.21% | ||
| 2022-04-08 | Sale | EVP and Co-President of Retail | 5,719 0.0004% | $105.00 | $600,495 | -9.75% | ||
| 2022-04-04 | Sale | EVP/Pres, Health Care Benefits | 16,161 0.0012% | $100.13 | $1.62M | -3.64% | ||
| 2022-03-30 | Sale | EVP and Co-President of Retail | 5,346 0.0004% | $104.70 | $559,726 | -6.88% | ||
| 2022-03-17 | Sale | EVP and Co-President of Retail | 2,935 0.0002% | $106.65 | $313,018 | -10.72% | ||
| 2022-03-15 | Sale | EVP & General Counsel | 51,361 0.0038% | $105.00 | $5.39M | -9.33% | ||
| 2022-02-10 | director | 1,000 <0.0001% | $105.90 | $105,904 | -5.98% | |||
| 2022-02-03 | Sale | EVP and Chief Medical Officer | 47,937 0.0037% | $110.00 | $5.27M | -8.69% | ||
| 2022-02-01 | Sale | EVP&President-PharmacyServices | 21,386 0.0016% | $106.50 | $2.28M | -6.46% | ||
| 2022-01-28 | Sale | SVP, Cont & Chief Acct Officer | 6,059 0.0005% | $109.00 | $660,431 | -8.97% | ||
| 2022-01-27 | Sale | EVP & Chief Operating Officer | 68,482 0.0053% | $107.50 | $7.36M | -6.85% |
Insider Historical Profitability
| Shah Prem S | EVP and Pres-Pharm, Consumer W | 39765 0.0032% | $53.22 | 0 | 4 | |
| LUDWIG EDWARD J | director | 21630 0.0017% | $53.22 | 7 | 0 | +11.69% |
| Mahoney Michael F | director | 9356 0.0007% | $53.22 | 1 | 0 | |
| RYAN THOMAS M | Non-Executive Chairman | 764683 0.0608% | $53.22 | 2 | 20 | +6.97% |
| GOLDSTEIN STANLEY P | director | 660206 0.0525% | $53.22 | 0 | 17 | |
| Moriarty Thomas M | EVP & General Counsel | 608129 0.0483% | $53.22 | 1 | 9 | +14.92% |
| MERLO LARRY J | director | 524026 0.0416% | $53.22 | 0 | 24 | |
| Lynch Karen S | President and CEO | 431392 0.0343% | $53.22 | 1 | 1 | +2.03% |
| HEADRICK ROGER L | director | 324262 0.0258% | $53.22 | 1 | 0 | +3.14% |
| RICKARD DAVID B | Chief Financial Officer | 207179 0.0165% | $53.22 | 0 | 3 | |
| PICCOLO C A | director | 181461 0.0144% | $53.22 | 0 | 2 | |
| Brennan Troyen A | EVP and Chief Medical Officer | 138246 0.011% | $53.22 | 1 | 25 | |
| CRAWFORD EDWIN M | Chairman | 135498 0.0108% | $53.22 | 0 | 2 | |
| DORMAN DAVID W | director | 122302 0.0097% | $53.22 | 2 | 0 | +12.47% |
| Boratto Eva C | EVP & CFO | 115331 0.0092% | $53.22 | 0 | 13 | |
| BROWN C DAVID II | director | 111252 0.0088% | $53.22 | 2 | 4 | +11.66% |
| Lotvin Alan | EVP&President-PharmacyServices | 109183 0.0087% | $53.22 | 1 | 5 | +6.03% |
| Roberts Jonathan C | EVP & Chief Operating Officer | 107115 0.0085% | $53.22 | 0 | 15 | |
| MURRAY TERRENCE | director | 80506 0.0064% | $53.22 | 4 | 3 | +6.21% |
| WILLIAMS KRISTEN GIBNEY | director | 64679 0.0051% | $53.22 | 1 | 3 | +7.56% |
| COSBY MARK | EVP & President-CVS/pharmacy | 45955 0.0037% | $53.22 | 0 | 1 | |
| Bisaccia Lisa | EVP and Chief HR Officer | 46588 0.0037% | $53.22 | 0 | 13 | |
| Foulkes Helena | EVP & President-CVS Pharmacy | 45107 0.0036% | $53.22 | 0 | 14 | |
| Joyner J. David | EVP, Sales & Account Services | 45399 0.0036% | $53.22 | 0 | 5 | |
| Finke Daniel P | EVP/Pres, Health Care Benefits | 32150 0.0026% | $53.22 | 0 | 3 | |
| GERRITY THOMAS P | director | 31165 0.0025% | $53.22 | 0 | 5 | |
| LAUTENBACH TERRY R | director | 27915 0.0022% | $53.22 | 0 | 1 | |
| Flum Joshua Matthew | EVP, ENT STRATEGY & DIGITAL | 25001 0.002% | $53.22 | 0 | 2 | |
| Lofberg Per GH | EVP | 23419 0.0019% | $53.22 | 5 | 3 | +6.93% |
| BANKS EDWIN M | director | 23187 0.0018% | $53.22 | 0 | 3 | |
| GOLD STEPHEN J | EVP & CIO | 21560 0.0017% | $53.22 | 1 | 2 | +6.79% |
| FERDINANDI V MICHAEL | Senior Vice President | 16021 0.0013% | $53.22 | 1 | 5 | +36.06% |
| AGUIRRE FERNANDO | director | 16222 0.0013% | $53.22 | 2 | 0 | +11.6% |
| Finucane Anne A. | director | 14719 0.0012% | $53.22 | 0 | 3 | |
| MCGUIGAN STUART M | SVP and CIO | 10967 0.0009% | $53.22 | 1 | 3 | +14.83% |
| Finley Sara | SVP, Gen Counsel | 8525 0.0007% | $53.22 | 0 | 1 | |
| Sussman Andrew | EVP, Clinical Services | 8697 0.0007% | $53.22 | 0 | 8 | |
| Clark James David | SVP, Cont & Chief Acct Officer | 4698 0.0004% | $53.22 | 0 | 7 | |
| Mayhew Jonathan E. | EVP - Transformation | 4732 0.0004% | $53.22 | 0 | 1 | |
| WEISHAR GREGORY S | Vice President | 4010 0.0003% | $53.22 | 0 | 1 | |
| SWIFT RICHARD J | director | 3258 0.0003% | $53.22 | 1 | 1 | +34.75% |
| Hourican Kevin | EVP & President, CVS Pharmacy | 3571 0.0003% | $53.22 | 0 | 1 | |
| BODINE CHRIS W | Executive Vice President | 2583 0.0002% | $53.22 | 1 | 7 | +1.83% |
| MILLON JEAN PIERRE | director | 0 0% | $53.22 | 0 | 4 | |
| SGARRO DOUGLAS A | EVP and CLO | 214 0% | $53.22 | 0 | 13 | |
| SOLBERG LARRY D | Senior Vice President | 0 0% | $53.22 | 0 | 3 | |
| MCLURE HOWARD A | President, Caremark Pharm Serv | 0 0% | $53.22 | 0 | 7 | |
| VERRECCHIA ALFRED J | director | 0 0% | $53.22 | 0 | 1 | |
| Spalding William R | EVP Caremark Pharmacy Services | 182 0% | $53.22 | 0 | 1 | |
| Denton David M | EVP and CFO | 403 0% | $53.22 | 1 | 8 |
Institutional Investor Ownership
| The Vanguard Group | $9.26B | 9.25 | 116.12M | -1.34% | -$125.92M | 0.17 | |
| BlackRock | $6.95B | 6.94 | 87.1M | +0.09% | +$6.26M | 0.15 | |
| State Street | $4.39B | 4.38 | 55M | -0.36% | -$15.86M | 0.18 | |
| Capital World Investors | $3.49B | 3.49 | 43.78M | +7.97% | +$257.8M | 0.58 | |
| Dodge & Cox | $3.27B | 3.27 | 41.01M | +34.85% | +$845.39M | 1.9 | |
| Capital International Investors | $3.02B | 3.02 | 37.92M | +12.54% | +$337.08M | 0.61 | |
| Fidelity Investments | $2.75B | 2.74 | 34.42M | -8.98% | -$270.83M | 0.18 | |
| Morgan Stanley | $2.32B | 2.31 | 29.04M | -5.14% | -$125.65M | 0.17 | |
| Geode Capital Management | $2.02B | 2.02 | 25.38M | +3.56% | +$69.37M | 0.17 | |
| Bank of America | $1.29B | 1.29 | 16.16M | +5.92% | +$72.05M | 0.12 | |
| Invesco | $1.17B | 1.17 | 14.64M | -8.29% | -$105.55M | 0.24 | |
| JPMorgan Chase | $1.12B | 1.12 | 14.09M | +2.31% | +$25.33M | 0.1 | |
| Capital Research Global Investors | $1.05B | 1.05 | 13.14M | +1.42% | +$14.7M | 0.24 | |
| Northern Trust | $1.03B | 1.03 | 12.91M | -5.71% | -$62.3M | 0.17 | |
| Legal & General | $932.52M | 0.93 | 11.69M | -0.94% | -$8.84M | 0.22 | |
| Royal Bank of Canada | $920.04M | 0.92 | 11.54M | -6.04% | -$59.09M | 0.22 | |
| Charles Schwab | $904.17M | 0.92 | 11.54M | -10.91% | -$110.73M | 0.2 | |
| Franklin Templeton Investments | $912.95M | 0.91 | 11.45M | +8.34% | +$70.26M | 0.27 | |
| T. Rowe Price | $853.36M | 0.85 | 10.7M | +0.12% | +$1.06M | 0.11 | |
| Goldman Sachs | $806.18M | 0.81 | 10.11M | -21.44% | -$220.03M | 0.15 | |
| BNY Mellon | $802.87M | 0.8 | 10.07M | -3.2% | -$26.57M | 0.15 | |
| Dimensional Fund Advisors | $774.43M | 0.77 | 9.71M | -0.36% | -$2.82M | 0.2 | |
| Nordea Investment Management Ab | $660.44M | 0.66 | 8.28M | -8% | -$57.39M | 0.78 | |
| UBS | $643.03M | 0.64 | 8.06M | +9.99% | +$58.43M | 0.19 | |
| LAZARD ASSET MANAGEMENT LLC | $534.28M | 0.53 | 6.7M | +1.89% | +$9.91M | 0.71 | |
| Hotchkis & Wiley Capital Management | $530.23M | 0.53 | 6.65M | -0.72% | -$3.87M | 1.77 | |
| Pacer Advisors Inc | $488.3M | 0.49 | 6.12M | +11.04% | +$48.57M | 1.24 | |
| LSV Asset Management | $473.6M | 0.47 | 5.94M | -0.45% | -$2.16M | 0.98 | |
| Ubs Asset Management Americas Inc | $449.52M | 0.45 | 5.64M | -10.49% | -$52.66M | 0.16 | |
| Voya Investment Management | $442.94M | 0.44 | 5.55M | +573.76% | +$377.2M | 1.52 | |
| Macquarie Group | $427.54M | 0.43 | 5.36M | -4.94% | -$22.23M | 0.39 | |
| Deutsche Bank | $414.26M | 0.41 | 5.19M | -21.14% | -$111.06M | 0.19 | |
| Wells Fargo | $411.44M | 0.41 | 5.16M | -5.52% | -$24.04M | 0.11 | |
| Harris Associates | $345.03M | 0.35 | 4.33M | +3.97% | +$13.18M | 0.56 | |
| Amundi | $292.02M | 0.34 | 4.21M | -3.82% | -$11.6M | 0.12 | |
| AQR Capital | $314.89M | 0.32 | 3.96M | -10.17% | -$35.66M | 0.49 | |
| ClearBridge Investments | $313.01M | 0.31 | 3.92M | +28.83% | +$70.04M | 0.25 | |
| Swiss National Bank | $307.38M | 0.31 | 3.85M | -4.05% | -$12.96M | 0.2 | |
| Barclays | $303.94M | 0.3 | 3.81M | -11.2% | -$38.34M | 0.14 | |
| Nuveen | $302.25M | 0.3 | 3.79M | -0.53% | -$1.61M | 0.09 | |
| Sumitomo Mitsui Trust Holdings | $297.85M | 0.3 | 3.73M | +0.51% | +$1.5M | 0.2 | |
| Ameriprise Financial | $282.44M | 0.28 | 3.53M | -25.5% | -$96.66M | 0.08 | |
| Envestnet Asset Management Inc | $280.02M | 0.28 | 3.51M | +37.31% | +$76.09M | 0.11 | |
| PRIMECAP Management Co | $270.82M | 0.27 | 3.4M | -1.41% | -$3.86M | 0.2 | |
| BB&T | $244.35M | 0.24 | 3.06M | +31.54% | +$58.58M | 0.37 | |
| HSBC | $234.91M | 0.24 | 2.95M | +23.16% | +$44.18M | 0.17 | |
| CalPERS | $221.39M | 0.22 | 2.78M | -2.24% | -$5.07M | 0.16 | |
| RhumbLine Advisers | $218.24M | 0.22 | 2.74M | +0.52% | +$1.13M | 0.2 | |
| Neuberger Berman | $213.35M | 0.21 | 2.67M | -0.61% | -$1.3M | 0.18 | |
| Raymond James Associates | $212.08M | 0.21 | 2.66M | -8.5% | -$19.7M | 0.14 |